Dupixent access in India

Quick orientation

Dupixent is the Sanofi and Regeneron biologic dupilumab, an IL-4 receptor alpha blocker that interrupts IL-4 and IL-13 signaling at the center of type 2 inflammation. The US FDA has approved it across six indications driven by the same underlying type 2 biology: atopic dermatitis (from infants 6 months and older through adults), moderate-to-severe asthma with eosinophilic phenotype or oral-corticosteroid dependence, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (down to children 1 to 11 years weighing at least 15 kg), prurigo nodularis, and COPD with type 2 inflammation. India families seek Dupixent when the indication, the pen presentation, the pediatric weight band, or the payer position locally falls short of what the prescribing specialist has documented. The legal route is the Central Drugs Standard Control Organization (CDSCO) personal importation framework under Rule 36 of the Drugs and Cosmetics Rules 1945, using Form 12A application and Form 12B permit. Reserve Meds coordinates US-side sourcing, the documentation kit, validated cold-chain shipment, and a single named coordinator for the case.

Reserved for you.

Why patients in India need Dupixent via NPP

Dupixent is locally registered in India through CDSCO for principal indications, with Sanofi commercializing the brand through its India affiliate. The access gap is not "unregistered drug." It is structural in three ways the country module describes: registered but not stocked in the specific pen presentation a weight-banded pediatric patient requires, registered for one indication while the treating specialist is prescribing for another FDA-approved use, or registered with private-payer step therapy that the family does not meet on the local clock. India's strong domestic biosimilar industry covers adalimumab (Exemptia, Adfrar) and ustekinumab, but Dupixent has no biosimilar pathway in India today, so the only legal route to the molecule is the originator Sanofi and Regeneron product.

The drug module explains why the cross-border demand persists even where the brand is locally registered. Newer indications, particularly pediatric atopic dermatitis under 6 years, pediatric eosinophilic esophagitis under 12 years, prurigo nodularis, and the 2024 COPD indication, reach Indian registration on a lag of 12 to 36 months after FDA approval. A 25 kg child needing the 200 mg pen for atopic dermatitis often finds only the 300 mg pen on the local market. Insurers including Star Health, HDFC ERGO, ICICI Lombard, and Niva Bupa handle these requests case by case and do not reimburse a personal import as a standard line item. For families spanning Hyderabad, Mumbai, Bangalore, and the Gulf, the cross-border Rule 36 pathway is the documented route. The helminth precaution in the FDA label is operationally relevant in parts of the Indian population and is addressed in the prescribing physician's pre-initiation workup and the clinical justification letter.

The CDSCO Rule 36 personal importation pathway for Dupixent

The legal foundation for personal import of a small quantity of medicine into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits import of small quantities of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient.

The mechanism is documented and accessible. Form 12A is the application for a permit to import a small quantity of a drug for personal use under the second proviso to Rule 36. Form 12B is the permit itself, issued by the office of the Drugs Controller General of India (DCGI) at FDA Bhawan, Kotla Road, New Delhi, or by a designated CDSCO Port Office. The application is accompanied by a prescription from a Registered Medical Practitioner (RMP) showing the RMP's National Medical Commission (NMC) registration number and the quantity required for treatment. The quantity of any single drug imported shall not exceed one hundred average doses per application.

CDSCO's published guidance states the Form 12B permit is issued on a priority basis, typically within one to two days for routine applications where the documentation is complete. In practice, families and hospitals plan for a two to four week window from physician decision to dispensed medicine, because the bulk of the elapsed time is upstream documentation assembly and downstream international logistics rather than the regulator's stamp.

For Dupixent specifically, the clinical justification letter centers on three angles. First, the documented FDA-approved indication for which the drug is being prescribed (atopic dermatitis at the patient's age band including infants 6 months and older, asthma with eosinophilic phenotype, CRSwNP, EoE with the age and weight cut-offs, prurigo nodularis, or COPD with type 2 inflammation), with the patient's weight band noted where relevant. Second, prior therapy and response history: which topical or systemic agents have been tried in atopic dermatitis, which inhaled and oral steroids in asthma, which dietary or PPI strategies in EoE. Third, baseline workup including the helminth screen documented for the Indian context (since dupilumab may impair the immune response to helminths, patients with known helminth infection should be treated before initiating), the eosinophil count where applicable to asthma or EoE, and the dosing plan with the specific pen presentation requested. Notably absent from this list is a tuberculosis screen: unlike most other immunology biologics, Dupixent does not require TB screening before initiation, which simplifies the workup for India patients relative to TNF inhibitors, IL-23 blockers, or JAK inhibitors. A complete CDSCO application also includes the treating physician's NMC registration number and state council registration where required, patient identifier and supporting medical records, product details (brand Dupixent, INN dupilumab, manufacturer Sanofi and Regeneron, strength, quantity, batch where available), the dispensing facility's drug licence, and a chain-of-custody plan from the US source to the Indian dispensing pharmacy.

Where Dupixent gets dispensed in India

India's tertiary specialty hospital network handles named-patient cold-chain biologics as established workflow. Institutions with established import pharmacy desks include the All India Institute of Medical Sciences (AIIMS) in New Delhi (apex public-sector institution and Centre of Excellence under the National Policy for Rare Diseases), Tata Memorial Centre in Mumbai (anchor of the National Cancer Grid, though Dupixent indications sit in dermatology, pulmonology, allergy, and gastroenterology rather than oncology), Apollo Hospitals (Chennai flagship, plus Delhi, Bangalore, Hyderabad, Kolkata), Fortis Memorial Research Institute in Gurgaon and the broader Fortis network, Medanta in Gurgaon, Kokilaben Dhirubhai Ambani Hospital in Mumbai, MGM Healthcare in Chennai, Christian Medical College (CMC) in Vellore, and Manipal Hospitals in Bangalore.

For Dupixent, the most relevant clinical departments are dermatology, pulmonology and severe asthma services, otorhinolaryngology for CRSwNP, gastroenterology for EoE, and pediatrics for the age-banded atopic dermatitis (down to infants 6 months and older) and EoE populations. Cold-chain capability at 2 to 8 degrees Celsius with continuous temperature logging through customs handoff is the gating capability. If the treating specialist is at a smaller institution without an import pharmacy desk, the practical route is to work with one of the centres above or with a CDSCO-licensed specialty importer in Mumbai, Delhi, or Bangalore that handles the filing and chain-of-custody documentation on behalf of the smaller hospital.

Real cost picture for Dupixent in India

US wholesale acquisition cost for Dupixent is approximately USD 3,993 per 300 mg pen carton (two-pack), with annual WAC in the USD 37,000 to USD 43,000 range for the most common adult atopic dermatitis regimen of 300 mg every two weeks. International logistics for cold-chain biologic shipment to India typically adds USD 400 to USD 1,500 per consignment depending on validated packout, temperature logger configuration, and lane. Regulatory documentation handling, Indian customs handling at the destination airport (commonly Delhi, Mumbai, Bangalore, Chennai, or Hyderabad), and the Reserve Meds concierge fee are separate transparent line items.

India invoices land in INR with the rupee floating against the dollar; in May 2026 USD/INR is in the 94 to 95 range. India's Union Budget 2026-27 expanded customs duty exemptions on life-saving medicines, and GST on most life-saving medicines is 5%; biologic immunology agents generally fall under the standard medicines bracket and the specific HSN code is confirmed at the documentation stage. None of Star Health, HDFC ERGO, ICICI Lombard, or Niva Bupa reimburse a Rule 36 personal import as a standard line item; the default posture is cash-pay, with documentation structured so the family can pursue reimbursement after the fact if the plan allows.

Typical timeline for Dupixent in India

For Dupixent, total elapsed time from the prescribing specialist's decision to the dispensed pen typically runs two to four weeks. The Form 12B permit itself issues in one to two days on routine documentation per CDSCO's published priority track. The bulk of the timeline is documentation assembly with the treating specialist (helminth screen, indication justification, prior therapy summary, dosing plan), US-side sourcing alignment with Sanofi or Regeneron's specialty channel, validated cold-chain packout, international shipment, customs review of the Form 12B permit and any cold-chain logger records at the port of entry, and dispensing pharmacy receipt under its drug licence. Cold-chain shipments add two to three days versus ambient on the international logistics leg because of the validated packout and the lane discipline required to keep the 2 to 8 degrees Celsius envelope intact through customs. Pediatric cases with weight-banded pen presentations may add a day or two for pen-format alignment with the US specialty channel.

What your physician needs to provide

The treating Registered Medical Practitioner in India with a valid NMC registration number assembles the clinical package that travels with the Form 12A application. For Dupixent that package includes: the patient's diagnosis and the FDA-approved indication being prescribed (atopic dermatitis with age band from 6 months and older, asthma with phenotype, CRSwNP, EoE with age and weight cut-offs, prurigo nodularis, or COPD with type 2 inflammation); severity assessment (EASI or IGA in atopic dermatitis, blood eosinophil count and oral steroid status in asthma, dysphagia and biopsy findings in EoE, lesion count and itch scale in prurigo nodularis, exacerbation history and eosinophil count in COPD); the helminth screen result documented for the Indian patient context where clinically relevant, since dupilumab may impair the immune response to helminths and known infection should be treated before initiation; prior therapy and response history; the dosing plan with the specific pen presentation requested (100 mg, 150 mg, 200 mg, or 300 mg), the dose and interval per the FDA label for the indication, and the weight band where pediatric; the patient education plan covering home refrigeration, allowing the pen to reach room temperature for 30 to 45 minutes before injection, injection technique, and sharps disposal; and the prescription with NMC registration number. The Reserve Meds documentation kit references each of these elements so the package does not loop back through CDSCO for missing data.

Common questions about Dupixent in India

Will Star Health, HDFC ERGO, ICICI Lombard, or Niva Bupa cover Dupixent imported under Rule 36?
Each plan handles named-patient imports case by case. None of the major private insurers reimburse a Rule 36 personal import as a standard line item. Some have reimbursed full or partial drug cost when the underlying medicine is on their formulary and the import route was a stocking workaround. Cash-pay is the default posture; Reserve Meds provides the documentation so the family or hospital can pursue reimbursement after the fact if the plan allows.

Will my CGHS or ESIC entitlement cover this?
CGHS provides for life-saving and anti-cancer medicines not in the standard formulary to be considered by an Expert Committee under Special DG (DGHS), case by case. Dupixent indications are immunology and respiratory rather than oncology and the route is rarely structured for routine personal-import reimbursement. Check eligibility with your CGHS Wellness Centre before assuming coverage.

Can a private dermatology, pulmonology, or pediatric specialist sign the prescription?
Yes. Any Registered Medical Practitioner with a valid NMC registration number can support a Form 12A application. Specialists at AIIMS, Apollo, Fortis, Medanta, Kokilaben, MGM, CMC Vellore, and Manipal sign these letters routinely as part of institutional workflow. Pediatric atopic dermatitis cases for infants 6 months and older are handled at the institutions with established pediatric dermatology and pediatric allergy capability.

Does Dupixent require tuberculosis screening before initiation?
No. Unlike most other immunology biologics (TNF inhibitors, IL-23 blockers, JAK inhibitors), Dupixent does not require TB screening before initiation. The FDA label calls for baseline assessment for helminth infection risk in patients from endemic regions, which is more operationally relevant for parts of India than a TB screen. Patients with known helminth infection should be treated before initiating Dupixent because dupilumab may impair the immune response to helminths.

What is the safety profile and monitoring requirement?
The most commonly reported adverse reactions across the label include injection-site reactions, conjunctivitis (especially in atopic dermatitis), oral herpes, eosinophilia, and arthralgia. Serious hypersensitivity reactions including anaphylaxis have been reported but are rare. Routine laboratory monitoring is not required by the FDA label. Eye symptoms should be evaluated by an ophthalmologist if conjunctivitis is persistent. Patients on systemic or topical corticosteroids for asthma or atopic dermatitis should not abruptly discontinue them when starting Dupixent. Adverse event reporting in India runs through the Pharmacovigilance Programme of India (PvPI) coordinated by the Indian Pharmacopoeia Commission; the reporting obligation stays with the prescribing physician.

Are alternatives in India a meaningful question for Dupixent?
In atopic dermatitis, alternatives include tralokinumab (Adbry), lebrikizumab (Ebglyss), and JAK inhibitors such as upadacitinib (Rinvoq) and abrocitinib. In asthma, alternatives include omalizumab, mepolizumab, reslizumab, benralizumab, and tezepelumab. The choice rests with the prescribing specialist; Reserve Meds coordinates the drug the specialist has named and does not direct substitution.

Where Reserve Meds fits in Dupixent cases

Reserve Meds is a US-based concierge coordinator. We do not replace the treating specialist, we do not replace CDSCO, and we do not replace the hospital pharmacy or the licensed importer. For Dupixent cases destined for India, we orchestrate US-side sourcing of the originator Sanofi and Regeneron pen presentation that matches the prescription, the documentation kit the physician needs to file under Rule 36, validated cold-chain international logistics with continuous temperature monitoring through the customs handoff at Delhi, Mumbai, Bangalore, Chennai, or Hyderabad, and a single named coordinator who carries the case from first contact through dispensed medicine and into the reporting period. For families that span multiple cities, including the common Hyderabad-Mumbai-Bangalore-Dubai configuration, one coordinator and one case file replace the ad-hoc coordination that otherwise lives across WhatsApp threads and pharmacy desks.

Next step

If you are a family member, a treating physician, or a hospital pharmacy considering Dupixent for an India case under Rule 36, the request route is a short intake on the Reserve Meds portal. We respond within 24 to 48 hours with eligibility and the documentation kit for your specialist.

Start a Dupixent India request

Reserved for you.